San Diego, CA – February 1st, 2010 - Avineuro Pharmaceuticals, Inc. announced today an initiation of Phase II clinical studies of AVN-101, a potent multi-target small molecule for treatment of Alzheimer’s disease and anxiety. In Phase I studies AVN-101 was well tolerated in a wide range of doses and no adverse events were observed. The compound demonstrated excellent exposure and half-life of more than 14 hours. Avineuro Pharmaceuticals, Inc. will present early clinical results with AVN-101at ICAD 2010 in July and an update on its entire CNS portfolio at Bio-Europe Spring 2010 in Barcelona in March.
About Avineuro Pharmaceuticals, Inc.:
Avineuro discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry. Avineuro emphasizes a rational approach to drug discovery that combines modern medicinal chemistry with streamlined pre-clinical and clinical development studies, thus allowing a fast transition to proof-of-concept product candidates.
